Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine
M. Plaze, D. Attali, M. Prot, A.-C. Petit, M. Blatzer, F. Vinckier, L. Levillayer, F. Perin-Dureau, A. Cachia, G. Friedlander, F. Chretien, E. Simon-Loriere, R. Gaillard
This study tests chlorpromazine's antiviral effect on SARS-CoV-2 in human and monkey cells, finding an IC50 of ~10M and suggesting its potential repurposing for COVID-19 treatment.
bioRxiv · May 5, 2020Microbiology